Please assess the completion status of the following clinical trial:

Trial Title: Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is at least 18 years old with refractory/relapsed AML~  * If untreated AML, patient is older than 60 years old and not a candidate for standard chemotherapy~* Patient is at least 4 weeks from prior treatment and has recovered from all prior treatment side effects~* Patient has no known liver or kidney problems~* Patient knows of no reason they can not receive transfusions of blood clotting cells (platelets)~* Patient is able to swallow capsules~* Patients both male and female are willing to practice birth control during the study~Exclusion Criteria:~* Patient has received prior treatment with valproic acid, decitabine or azacitidine~* Being is less than 18 years of age or if patient has untreated AML is below 60 years of age~* Patient is a women who is pregnant or breastfeeding. Patient has an active infection that requires antibiotics~* Patient has uncontrolled illness including but not limited to the following: heart problems (congestive heart failure, unstable angina pectoris, cardiac arrhythmia), inflammation of the pancreas; a mental or social condition that may interfere with patient following study procedures~* Patient has known human immunodeficiency virus (HIV) infection or HIV-related malignancy. Patient has a known history of hepatitis B or C infection~* Patient currently has another active cancer other than certain types of skin cancer~* Patient is heterosexual and able to have a child and is unwilling to practice birth control during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1: Vorinostat (sequential) (Type: EXPERIMENTAL): Vorinostat 400 mg capsules once daily given 7, 10 or 14 days in 28 day cycles. Up to 24 months of treatment.~Decitabine IV 20 mg/m\^2 daily for 5 days in each 28 day cycle. Up to 24 months of treatment.
- Cohort 2: Vorinostat (concurrent) (Type: EXPERIMENTAL): Vorinostat 400 mg capsules once daily given 7 days, 14 days with 8 day break after first 7 days or 14 days without break, out of 28 day cycles.~Decitabine IV 20 mg/m\^2 daily for 5 days in each 28 day cycle. Up to 24 months of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).